X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8544) 8544
Book Chapter (42) 42
Magazine Article (24) 24
Newsletter (16) 16
Book / eBook (4) 4
Dissertation (3) 3
Newspaper Article (3) 3
Publication (3) 3
Reference (3) 3
Conference Proceeding (2) 2
Report (2) 2
Web Resource (2) 2
Data Set (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6275) 6275
female (3906) 3906
male (3144) 3144
animals (3032) 3032
immunology (2393) 2393
adjuvants, immunologic - administration & dosage (2307) 2307
adjuvants, immunologic - adverse effects (2196) 2196
adult (2081) 2081
middle aged (2073) 2073
adjuvants, immunologic - therapeutic use (1894) 1894
vaccines (1712) 1712
aged (1462) 1462
mice (1454) 1454
treatment outcome (1202) 1202
cancer (1135) 1135
immunotherapy (1123) 1123
vaccination (1109) 1109
oncology (1073) 1073
medicine, research & experimental (1069) 1069
adjuvant (1005) 1005
adjuvants, immunologic - pharmacology (1000) 1000
antigens (940) 940
adjuvants (900) 900
immunization (869) 869
adolescent (783) 783
adjuvants, immunologic (779) 779
vaccine (747) 747
health aspects (742) 742
care and treatment (722) 722
analysis (706) 706
research (706) 706
immunogenicity (702) 702
pharmacology & pharmacy (676) 676
immune response (669) 669
dendritic cells (616) 616
safety (613) 613
clinical trials (608) 608
allergy and immunology (582) 582
proteins (568) 568
chemotherapy (566) 566
mice, inbred balb c (543) 543
medicine & public health (532) 532
therapy (525) 525
immune system (519) 519
young adult (497) 497
infectious diseases (491) 491
cytokines (482) 482
aged, 80 and over (470) 470
surgery (461) 461
child (458) 458
antibodies (451) 451
medical research (444) 444
double-blind method (438) 438
double-blind (430) 430
immunity (428) 428
time factors (425) 425
influenza (423) 423
influenza vaccines - immunology (420) 420
infection (417) 417
medicine (412) 412
drug therapy (403) 403
clinical trials as topic (398) 398
lymphocytes (396) 396
studies (396) 396
antibodies, viral - blood (393) 393
efficacy (392) 392
immune-responses (390) 390
rats (390) 390
dermatology (385) 385
tumors (384) 384
infections (377) 377
t cells (373) 373
disease models, animal (367) 367
inflammation (362) 362
follow-up studies (360) 360
influenza, human - prevention & control (351) 351
disease (348) 348
research article (347) 347
influenza vaccines - adverse effects (341) 341
risk factors (335) 335
bcg vaccine - adverse effects (333) 333
influenza vaccines - administration & dosage (330) 330
melanoma (325) 325
chemotherapy, adjuvant (321) 321
prospective studies (314) 314
prevention (311) 311
medicine, general & internal (310) 310
multiple sclerosis (310) 310
children (306) 306
mice, inbred c57bl (303) 303
cells (302) 302
dose-response relationship, drug (302) 302
t-lymphocytes - immunology (300) 300
responses (299) 299
combined modality therapy (297) 297
interferon (296) 296
biotechnology & applied microbiology (294) 294
immune-response (294) 294
drug therapy, combination (292) 292
trial (291) 291
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8213) 8213
Russian (147) 147
German (108) 108
French (88) 88
Japanese (77) 77
Spanish (63) 63
Chinese (26) 26
Italian (23) 23
Polish (17) 17
Portuguese (17) 17
Hebrew (7) 7
Ukrainian (7) 7
Danish (5) 5
Dutch (5) 5
Hungarian (5) 5
Swedish (5) 5
Finnish (3) 3
Romanian (3) 3
Norwegian (2) 2
Czech (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 19, pp. 1813 - 1823
In patients with surgically resected melanoma, those with BRAF mutations who received 1 year of oral adjuvant therapy with dabrafenib and trametinib had a 53%... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA-2B | PLACEBO | THERAPY | MEK INHIBITION | PHASE-III | DOUBLE-BLIND | HAZARD | IPILIMUMAB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Adjuvants, Immunologic - adverse effects | Young Adult | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Double-Blind Method | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasm Recurrence, Local | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Adolescent | Survival Analysis | Aged | Pyridones - therapeutic use | Melanoma - surgery | Mutation | Neoplasm Staging | Pyridones - adverse effects | Melanoma - mortality | Usage | Relapse | Patient outcomes | Analysis | Melanoma | Adjuvant treatment | Outcome and process assessment (Health Care) | Reports | Drug therapy | Cancer | Diseases | Medical imaging | Oncology | Metastasis | FDA approval | Kinases | Cancer therapies | Survival | Skin cancer | Metastases | Medical prognosis | Immunotherapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 380, Issue 9856, pp. 1829 - 1839
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 19, pp. 1824 - 1835
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2008, Volume 14, Issue 16, pp. 5284 - 5291
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 15, pp. 1418 - 1428
Journal Article
Vaccine, ISSN 0264-410X, 2016, Volume 34, Issue 3, pp. 313 - 319
...) vaccine with MF59 or saline placebo at 0, 1 and 6 months. • The vaccine was generally well tolerated, although local and systemic adverse events were significantly more common in the vaccine group... 
Allergy and Immunology | Cytomegalovirus | Vaccine | CMV gB | Adolescent | MEDICINE, RESEARCH & EXPERIMENTAL | IMMUNITY | PREVENTION | TRANSPLANT RECIPIENTS | IMMUNOLOGY | ADJUVANT | PLASMA | DNA | DISEASE | CMV INFECTION | Cytomegalovirus Vaccines - adverse effects | Adjuvants, Immunologic - administration & dosage | Vaccines, Subunit - genetics | Humans | DNA, Viral - analysis | Cytomegalovirus Infections - immunology | Vaccines, Synthetic - immunology | Cytomegalovirus Vaccines - administration & dosage | Antibodies, Viral - blood | Drug-Related Side Effects and Adverse Reactions - pathology | Adjuvants, Immunologic - adverse effects | Cytomegalovirus Infections - prevention & control | Vaccines, Synthetic - adverse effects | Blood - virology | Polymerase Chain Reaction | Polysorbates - administration & dosage | Female | Immunization Schedule | Vaccines, Subunit - adverse effects | Child | Cytomegalovirus Vaccines - genetics | Placebos - administration & dosage | Antigens, Viral - analysis | Polysorbates - adverse effects | Viral Envelope Proteins - genetics | Double-Blind Method | Vaccines, Synthetic - genetics | Squalene - administration & dosage | Urine - virology | Vaccines, Subunit - immunology | Squalene - adverse effects | Drug-Related Side Effects and Adverse Reactions - epidemiology | Vaccines, Subunit - administration & dosage | Viral Envelope Proteins - immunology | Vaccines, Synthetic - administration & dosage | DNA, Viral - genetics | Cytomegalovirus Vaccines - immunology | Clinical trials | Medical colleges | Vaccines | Teenage girls | Antigens | Cytomegalovirus infections | Vaccination | Urine | Confidence intervals | Substance abuse treatment | Consent | Hispanic Americans | Population | Infections | adolescent | vaccine | cytomegalovirus
Journal Article
Vaccine, ISSN 0264-410X, 2013, Volume 31, Issue 3, pp. 524 - 532
Highlights ► This Phase 1 trial evaluated the safety and immunogenicity of an RSV (F) nanoparticle vaccine. ► The vaccine was well-tolerated and no related... 
Allergy and Immunology | Respiratory syncytial virus (RSV) | Palivizumab | Fusion protein (F protein) | Competitive ELISA | SF9 insect cell | Microneutralization | Aluminum phosphate | Anti-F IgG | Nanoparticle vaccine | UNITED-STATES | MEDICINE, RESEARCH & EXPERIMENTAL | NEUTRALIZING ANTIBODIES | IMMUNE GLOBULIN | COTTON RATS | INFLUENZA | RISK | IMMUNOLOGY | F-GLYCOPROTEIN | INFANTS | INFECTION | YOUNG-CHILDREN | Recombinant Fusion Proteins - immunology | Single-Blind Method | Biotechnology | Respiratory Syncytial Virus Vaccines - immunology | Adjuvants, Immunologic - administration & dosage | Aluminum Compounds - adverse effects | Phosphates - administration & dosage | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Male | Nanoparticles - adverse effects | Vaccines, Synthetic - immunology | Antibodies, Viral - blood | Adjuvants, Immunologic - adverse effects | Young Adult | Respiratory Syncytial Virus Vaccines - adverse effects | Sf9 Cells | Technology, Pharmaceutical | Vaccines, Virosome - immunology | Vaccines, Synthetic - adverse effects | Placebos - adverse effects | Adult | Female | Placebos - administration & dosage | Recombinant Fusion Proteins - administration & dosage | Vaccines, Virosome - administration & dosage | Vaccines, Synthetic - genetics | Vaccines, Virosome - genetics | Animals | Aluminum Compounds - administration & dosage | Phosphates - adverse effects | Vaccines, Virosome - adverse effects | Respiratory Syncytial Virus Vaccines - administration & dosage | Adolescent | Recombinant Fusion Proteins - genetics | Nanoparticles - administration & dosage | Vaccines, Synthetic - administration & dosage | Respiratory Syncytial Virus Vaccines - genetics | Antibodies, Neutralizing - blood | Virus diseases | Phosphates | Vaccines | Immunoglobulin G | Enzyme-linked immunosorbent assay | Proteins | Nanoparticles | Infections | Index Medicus
Journal Article
Expert Review of Vaccines, ISSN 1476-0584, 07/2013, Volume 12, Issue 7, pp. 747 - 758
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 380, Issue 9856, pp. 1819 - 1828
Journal Article